Form D · Biotechnology
Novamind Ventures Inc.
Toronto, A6 · CIK 0001833397
Offering snapshot reported Nov 25, 2020 · SEC filing
- Reported sold
- $2.15M Offering amount: $2.15M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 10, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 25, 2020 | Initial | $2,153,247 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-381578
Total Offering Amount represents aggregate purchase price of 2,802,978 subscription receipts issued at C$1.00 on November 10, 2020. Exchange rate of US$1:C$1.3017.
C$1.00 Subscription Receipts, each Subscription Receipt is exercisable into 4 common shares without any additional consideration upon satisfaction of certain escrow release conditions.
Source: Form D, filed Nov 25, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Yaron Conforti | Director, Executive |
| Jesse Kaplan | Director |
| Reid Robison | Director, Executive |
| Yisroel Weinreb | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10 Wanless Ave, Suite 201
Toronto, A6, M4N 1V6
Toronto, A6, M4N 1V6